… for paclitaxel and … IB studies evaluated the synergistic use of everolimus for combined
therapies. Sun et al. evaluated n = 21 pretreated SCLC patients using a treatment with everolimus (…

… for relapsed small cell lung cancer (SCLC) patients remain a challenge, with limited clinical
benefit because of rapid tumor … Everolimus, an mTOR inhibitor, was evaluated in a phase II …

… We conducted a phase 1b study of vorolanib (300 or 400 mg … squamous cell cancer and 1
small cell lung cancer). Two … of vorolanib plus everolimus combination over everolimus alone …

… “combination” and “lung”. Anti-PD-1 monotherapies have shown improved survival compared
with docetaxel in patients with advanced non-small-cell lung cancer (NSCLC) previously …

… with carboplatin plus paclitaxel in a phase III study with or without … In addition, a phase 1b
study concerning the safety and … of lenvatinib plus everolimus or lenvatinib plus pembrolizumab …

… for small cell lung cancer (SCLC) and non-small-cell lung … , veliparib in combination with
carboplatin and paclitaxel was … ) have been tested in phase 1b study and found to be safe with …

… received everolimus at three different doses in combination with paclitaxel. At the dose of 5
mg once daily in combination with paclitaxel, everolimus showed an acceptable safety profile …

… 2 study of Papadimitrakopoulou [168] et al. evaluated the tolerability and disease control of
Everolimus and erlotinib in patients … A phase 1b trial about RAD001 combined with standard-…

… endometrial carcinoma, after establishing the maximum tolerated dose in a phase 1b
study. … or paclitaxel in patients with advanced endometrial cancer is recruiting (NCT03517449). …

… non-small cell lung cancer (NSCLC), small cell lung cancer (… of lenvatinib plus everolimus
in n = 20 patients with mRCC. … Another phase 1b study tested the combination of lenvatinib 24 …